AUS
NZ
UK
CA
USA
IND
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW), a late-stage biotechnology company dedicated to treating medical and aesthetic skin diseases, has successfully closed its previously announced private placement. The transaction involved the issuance and sale of 1,912,569 shares of common stock (or pre-funded warrants in lieu thereof) along with accompanying series A and short-term series B warrants to purchase up to the same number of shares. Each share was priced at $1.83, resulting in gross proceeds of approximately $3.5 million before deducting placement agent fees and other related expenses.
H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The series A warrants and series B warrants, both priced at $1.58 per share, are immediately exercisable. The series A warrants will expire five and a half years from their issuance date, while the series B warrants have an expiration period of eighteen months.
With this recent offering, Dermata has raised a total of approximately $7.8 million in gross proceeds since May 2024. The net proceeds from this private placement, combined with the company’s existing cash reserves, are expected to sustain operations through the second quarter of 2025. Dermata plans to allocate the funds toward a variety of initiatives, including ongoing research, pre-clinical studies, and clinical trials.
The company is focused on advancing its portfolio of biological and pharmaceutical technologies, which are aimed at addressing both medical and aesthetic skin conditions. The funds will also support licensing activities related to current and future product candidates, as well as the development of emerging technologies. In addition, Dermata is considering investments in or acquisitions of companies that align synergistically with its strategic vision.
This capital infusion will enable Dermata to accelerate its research and development efforts and enhance its capabilities in delivering innovative solutions to patients suffering from skin diseases. The biotechnology sector is known for its dynamic nature, and Dermata’s strategic approach positions it well for future growth in a competitive market.
As Dermata continues its mission to improve the lives of those with skin diseases, the recent funding marks a critical step in the company’s journey. With strong leadership and a clear focus on innovation, Dermata Therapeutics is poised to make significant strides in the biopharmaceutical industry.
